Concepedia

AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Richard B. Warren, A. Armstrong, M. Gooderham, B. Strober, D. Thaçi, S. Imafuku, H. Sofen, L. Spelman, N. J. Korman, M. Zheng,

Annals of the Rheumatic Diseases · 2022 · 10 citations · 1 references

DOIFull text

Open access

Concepts

References

1

AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

Richard B. Warren, A. Armstrong, M. Gooderham et al. · Annals of the Rheumatic Diseases · 2022 · 10 citations · Full text

, , +12